COVID-19, the disease caused by the SARS-CoV-2 virus, has stretched hospital and ICU resources to their limits in almost every country, and is so far responsible for 4.5 million documented deaths.
Bioreagents provider including assay kits, antibodies and chemicals
SARS-CoV-2 has been reported to lead to viral sepsis [ref. 1,2]. Additionally, severe COVID-19 cases are characterized by an hyperinflammatory response of the immune system, also called cytokine storm, whose pathology is very similar to bacterial sepsis [ref. 3].
Calprotectin is a heterodimer of two proteins: S100A8 (also known as calgranulin A) and S100A9 (also known as calgranulin B), that is associated with the inflammatory response to infection. Calprotectin has been identified as an early biomarker for sepsis, and is expressed upon activation of neutrophil granulocytes in response to inflammation and infection [ref. 4,5].
In the case of SARS-CoV-2, calprotectin levels have also been shown to be significantly higher in severe COVID-19 cases [ref. 7]. Recent evidence has shown a potential role for calprotectin, both as a diagnostic tool and also as a tool in determining the severity of COVID-19 cases [ref. 6]. Calprotectin could become a major diagnosis tool, allowing for the early prediction of viral sepsis in COVID-19 patients.
Bertin Bioreagent offers ELISA kit for calprotectin quantification in complex human samples (CatNo: A05083).

Bioreagents provider including assay kits, antibodies and chemicals
We gladly support you by keeping you updated on our latest products and developments